WSJ: Lilly banking on late-stage drugs

Share this article:

Eli Lilly CEO John Lechleiter says he's not ready to cut his firm's $5.3-billion R&D budget yet, but if the firm's late-stage pipeline doesn't pan out, that's exactly what he'll need to do.

Lilly is scheduled to report earnings Wednesday. In an interview with The Wall Street Journal, the CEO made no mention of another large-scale reorganization the likes of Merck's earlier this month.

The Indianapolis pharma spends 23% of revenue on R&D -- one of the highest R&D spending rates in pharma, according to the WSJ. It's risen 20% since 2009. 

The late-stage pipeline includes solanezumab for Alzheimer's, and three diabetes drugs: SGLT2 inhibitor empagliflozin, the dulaglutide GLP-1 and a Lantus-like long-acting form of insulin.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.